A biocompatible curable composition and a method of detecting a border of a tumor, a tissue of interest, or both including injecting the biocompatible curable composition and contacting the border of a tumor or a tissue, the biocompatible curable composition crosslinks to form a three-dimensional cured nanocomposite, and imaging the three-dimensional (3D) cured nanocomposite, and imaging the 3D cured nanocomposite by at least one of MRI, CT, ultrasound, and X-ray, to detect the border of the tumor or the tissue of interest or track tumor motion during radiotherapy treatment. The biocompatible curable composition comprising an organic polymer having a hydrolysable functional group, a metallic nanoparticle, and a polar or a non-polar solvent. A brachytherapy strand consisting of a biocompatible curable composition and a radio-isotope seed. The biocompatible curable composition is shaped into an elongated cylinder and forms a 3D cured nanocomposite with a radio-isotope seed embedded.

A biocompatible curable composition and a method of detecting a border of a tumor, a tissue of interest, or both including injecting the biocompatible curable composition and contacting the border of a tumor or a tissue, the biocompatible curable composition crosslinks to form a three-dimensional cured nanocomposite, and imaging the three-dimensional (3D) cured nanocomposite, and imaging the 3D cured nanocomposite by at least one of MRI, CT, ultrasound, and X-ray, to detect the border of the tumor or the tissue of interest or track tumor motion during radiotherapy treatment. The biocompatible curable composition comprising an organic polymer having a hydrolysable functional group, a metallic nanoparticle, and a polar or a non-polar solvent. A brachytherapy strand consisting of a biocompatible curable composition and a radio-isotope seed. The biocompatible curable composition is shaped into an elongated cylinder and forms a 3D cured nanocomposite with a radio-isotope seed embedded.

Effective treatments of pain and/or inflammation are provided. Through the administration of a porous biodegradable drug depot film, patch, strip or sponge being implantable within a nasal or sinus cavity and having pores sized to prevent the depot from functioning as a scaffold for tissue growth, one can reduce, prevent or treat pain and/or inflammation and prevent cells from infiltrating the drug depot and laying down scaffolding cells.

The present invention provides a method for the purification of .sup.227Th from a mixture comprising .sup.227Th and .sup.223Ra, said method comprising: i) preparing a first solution comprising a mixture of .sup.227Th and .sup.223Ra ions dissolved in an aqueous solution of first mineral acid; ii) loading said first solution onto a strong base anion exchange resin; iii) eluting .sup.223Ra from said strong base anion exchange resin using a second mineral acid in an aqueous solution; iv) optionally rinsing said strong base anion exchange resin using a first aqueous medium; v) eluting .sup.227Th from said strong base anion exchange resin using a third mineral acid in an aqueous solution whereby to generate a second solution comprising .sup.227Th. The invention further provides a purified .sup.227Th solution, a corresponding pharmaceutical formulation and methods of treatment of neoplastic disease.

A substance which regulates immune-checkpoints for use as a medicament for treatment of a tumor of a patient wherein the administration pattern of the medicament comprises administering a therapeutically effective amount of the substance to the tumor, in one or more sessions, and implanting seeds (204) carrying radium-224 in the tumor for intra-tumoral alpha-emitter radiotherapy less than two weeks from administering the substance.

A vascular inhibitor for use as a medicament for treatment of a tumor of a patient wherein the administration pattern of the medicament comprises administering a therapeutically effective amount of the vascular inhibitor to the patient, in one or more sessions, and implanting seeds (204) carrying radium-224 in the tumor for intra-tumoral alpha-emitter radiotherapy less than two weeks from administering the vascular inhibitor.

A radiotherapy device, including a flexible probe, adapted for being at least partially introduced into a body of a subject. A radionuclide selected from the group consisting of Radium-223 and Radium-224, is retainably embedded on or beneath a surface of the flexible probe.

A radiotherapy method, comprising positioning a predetermined amount of a radionuclide selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220, in proximity to and/or within a tumor of a subject, for a predetermined time period. The predetermined amount and the predetermined time period are selected sufficient for the radionuclide to administering a predetermined therapeutic dose of decay chain nuclei and alpha particles into the tumor.

An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.

An implantable system is disclosed that includes an encapsulated housing including a radioactive source. The encapsulated housing is internally coated with a light-generating coating that converts the radioactive energy to light, that is then output in vivo to a photodiode positioned proximate to at least part of the encapsulated housing in vivo. The photodiode is configured to generate electrical current from the light, which electrical current is output to a power conditioning circuit that is configured to use the electrical current as an input electrical current and to output power to a load in vivo. The encapsulated may also be internally coated, at least in part, with a light directing coating that causes light to be directed toward an optical lens that focuses the light on the photodiode. The radioactive source may be a gas having a low half-life and which poses no health risk to a patient if released.